Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 4/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26540650 | 0.88 | HINT1 (0.58) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL14003429 | 0.84 | HINT1 (0.57) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL13899230 | 0.84 | HINT1 (0.57) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL16807574 | 0.84 | HINT1 (0.63) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL19035716 | 0.83 | HPGD (0.61) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL19035717 | 0.82 | HINT1 (0.52) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL23010685 | 0.81 | HINT1 (0.54) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL22475009 | 0.79 | HINT1 (0.64) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL12740468 | 0.79 | HINT1 (0.55) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL22779004 | 0.78 | ALDH1A1 (0.48) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | HINT1 738/4885NT5E 191/4885HPGD 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.